Pharmaceutical Registration in Paraguay: DINAVISA, Mercosur Access and the Re-export Question

Paraguay is a small domestic market attached to a very large trading position, and the two are easy to confuse.

Roughly seven million people, moderate healthcare spend — that is the country. But Paraguay sits inside Mercosur, borders Brazil and Argentina, and Ciudad del Este is one of the more significant commercial crossing points in South America. A lot of interest in Paraguay is really interest in what moves through it.

Which raises a question you should settle before anything else: are you selling into Paraguay, or using Paraguay? Those need different structures, and only one of them is a registration project.

Paraguay is also, like Uruguay, a market where the regulator has been rebuilt fairly recently — worth knowing before you plan from older guidance.

Medicines in Paraguay are regulated by DINAVISA — Dirección Nacional de Vigilancia Sanitaria, which took over and expanded the functions of the former national health surveillance directorate.

DINAVISA handles sanitary registration of medicines, authorisation and inspection of pharmaceutical establishments, import control and pharmacovigilance.

DINAVISA participates as an observer agency at the Pan American Health Organization's Regional Reference Regulatory Authorities meetings, alongside agencies from Ecuador, El Salvador, Panama, Peru and Uruguay. As with Uruguay's AViSU, the direction of travel is towards a more autonomous, better-resourced agency aligned with regional standards — which generally means clearer procedures over time, and some turbulence while they settle.

A locally established entity must hold the registration and answer to DINAVISA. No registering from abroad.

The standard trade-off between distributor-held and independently-held registration applies, and in Paraguay it interacts with the re-export trade in a way that deserves care.

If your partner is active in cross-border commerce as well as domestic distribution, the registration you give them sits alongside a business whose incentives may not be confined to the Paraguayan market. That is not an accusation — it is a structural observation, and it means the territory and channel definitions in your agreement matter more here than in a market with cleaner boundaries.

Be specific in writing about where your product may be sold, by whom, and what happens if it appears somewhere it should not.

Expect a full technical dossier plus the documents establishing product and site standing:

• CoPP in WHO format, legalised for use in Paraguay.
• GMP certificate and manufacturing licence. Mercosur maintains its own Good Manufacturing and Distribution Practice framework — establish how your site's certification sits within it early.
• Finished product specification and validated method of analysis.
• Batch Certificate of Analysis.
• Stability data for the applicable climatic zone. Paraguay is hot and humid for much of the year, and data generated for temperate markets may not support your intended labelling.
• Bioequivalence data where required.
• Spanish labelling, artwork and patient information.
• Legalised power of attorney.

Because DINAVISA is a relatively recently reorganised agency, confirm the current requirement set and filing route directly rather than working from older published material.

Two levers, and they point the same way.

Mercosur. Paraguay is a founding member alongside Argentina, Brazil and Uruguay, and the bloc maintains harmonised technical work including Good Manufacturing and Distribution Practice standards. Work done for an Argentine or Brazilian filing is not wasted here.

Regional reference authorities. Of the eight PAHO Regional Reference Regulatory Authorities — ANMAT, ANVISA, Health Canada, ISP, INVIMA, CECMED, US FDA and COFEPRIS — two are Paraguay's immediate Mercosur neighbours and largest trading partners.

That makes the sequencing advice unusually concrete. If you are planning a Southern Cone entry, an ANMAT or ANVISA approval first makes the Paraguayan and Uruguayan filings materially easier. Starting with the small markets because they look less daunting is the more expensive order.

Extent of reliance is at DINAVISA's discretion and varies by product category.

Deficiency cycles drive elapsed time, and an agency still consolidating its procedures will generally produce more of them than a mature one.

Plan for that rather than being surprised by it, and get confirmations in writing — during any period of institutional change, informal guidance has a shorter shelf life than usual.

Registrations run for a fixed term and require renewal. If you are running a Mercosur portfolio, track renewals for all four member markets together; the one that gets missed is always the smallest.

Foreign documents require authentication before DINAVISA will accept them.

Paraguay is a party to the Hague Apostille Convention, as is India, so apostille rather than full consular legalisation will generally apply to public documents. Confirm before arranging consular appointments.

The familiar friction points:

• CoPP validity expiring mid-process.
• Commercial documents needing notarisation to qualify for apostille.
• Certified Spanish translation to local formal standards.
• Exact name consistency across every document.

If you are filing across Mercosur, sequence certificate issuance so one CoPP validity window covers as many filings as possible.

Paraguay maintains exceptional import routes for genuine clinical need the registered market cannot meet: no registered equivalent, shortage or supply interruption, public health need, orphan and rare disease products, and clinical trial material under its own authorisation.

The standard conditions apply — authorisation per consignment against a stated justification, applied for by the importing institution or licensed importer rather than by you, and not a substitute for registration where you intend to supply continuously.

Paraguay carries one risk that deserves plain speaking. A country with significant cross-border commerce and a small domestic market is an environment where product authorised for a specific exceptional purpose can find its way into channels it was not intended for. That is a reputational and regulatory exposure for the supplier, not only for the importer.

Practical protection: know who the end institution is, keep documentation that shows the chain from your consignment to that institution, and be wary of exceptional-import requests where the ultimate destination is vague or the quantities look larger than the stated justification would need. If the numbers do not match the story, ask.

Confirm current conditions with DINAVISA before relying on any of this.

An unregistered medicine may be imported for an individually identified patient, on a treating physician's responsibility, where no suitable registered alternative exists.

Typically required: prescription naming the patient, clinical justification, authority authorisation before the consignment moves, quantity limited to the treatment course, and batch CoA with provenance.

Compassionate use and expanded access for clinical-stage products sit under their own framework.

Paraguay's small population means rare-disease patient numbers are very low in absolute terms, so named patient supply is often the only realistic mechanism for those therapies — there will never be a commercial case for registering them. Asunción's air connections to São Paulo and Buenos Aires make routing manageable, which helps, though the final leg to patients outside the capital needs checking rather than assuming.

Further reading: our global guide to named patient import programmes, our named patient supply service, and our cold chain logistics page.

Public demand runs principally through the Ministry of Public Health and Social Welfare and through the social security institute, IPS (Instituto de Previsión Social), which covers formally employed workers and their families and is a substantial purchaser in its own right.

A valid registration is generally required to bid, so registration precedes tender participation rather than responding to it.

Paraguayan public procurement is price-competitive, and the practical implication is the same as in Bolivia: if your commercial case rests on a premium, test that assumption against the tender reality before investing in entry.

The PAHO Strategic Fund is available as a parallel route — pooled procurement for member states that have signed an agreement with the Organization, with eligibility resting on WHO Prequalification status at tender opening or approval by regulatory authorities of regional reference, rather than separate national registration. For WHO Prequalified products this deserves examination before committing to a registration project. Confirm current criteria with PAHO.

Our government and institutional tender supply page sets out the technical file requirements.

Match the documentation level to the route.

Paraguay is the market where the traceability of your own paperwork matters beyond the regulator. Keep records that let you demonstrate where a consignment went, not just that it was authorised.

• Planning from pre-DINAVISA guidance that no longer reflects current procedure.
• Vague territory and channel definitions in the distribution agreement, in a market with heavy cross-border commerce.
• Temperate-zone stability data used to support labelling in a hot, humid market.
• Filing Paraguay first in a Southern Cone programme, forgoing the reliance benefit an Argentine or Brazilian approval would have given.
• Expired or mismatched certificates.
• Exceptional import requests accepted without establishing the end destination.

Decide first whether this is a Paraguay project or a Mercosur logistics project. They are not the same and conflating them produces bad structures.

If it is a market entry, sequence it after Argentina or Brazil where you can. The reliance benefit is real and running the order backwards costs you it.

Write the territory and channel terms carefully. In most markets that clause is boilerplate; here it is doing actual work.

Check DINAVISA's current procedures directly rather than trusting older summaries, including confident ones.

And keep your own consignment records tight. The exposure in this market is not only regulatory — being able to show where your product went protects you as much as it protects anyone.

Not legal advice. Confirm current requirements with DINAVISA and take local advice before committing funds.